16 Jun 2021
Background The diagnostic market is estimated around $10bn/year, whereas, the global therapeutic antibody market stands around a staggering $50bn/year, and the research market accounts for $3bn/year. The average annual growth rate for the entire antibody applications in the past two decades has been over 5% and the recombinant sector has seen drastic growth. These statistics prove that biological innovations are aimed in these areas; to improve the antibody production process with regards to absolute yields, structural stability, and functional reliability of the outcome. The ever-growing interest towards the recombinant antibodies is seen for several reasons. This includes:
Results Instead of having a complete list of all the recent publications related to this filed, this research was done to examine the development of the latest and fastest growing strategies. These were explained with some examples, and compared with existing alternatives. All the solutions that may demonstrate intriguing opportunities are given the needed space. These solutions can investigate some important aspects of the production optimisation. However, the data we have isn’t sufficient and does not allow for a final judgment,
Conclusions The extract from this study is that there is a defined process of progressive diversification related to the antibody expression platforms. A lot of efforts have been made to yield the application-adapted immune-reagents directly, rather than the generic basic antibodies that require further in vitro modification steps prior to becoming stable. (Marco, 2015)
For more information about DNA extraction, RNA extraction, and high quality laboratory kits, get in touch with MBP inc today. We have all the best lab equipment for DNA testing and all other biological research methodologies.